Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
CA 2441845 C · Owner: Centro De Inmunologia Molecular · Inventors: Lombardero Valladares, Josefa; Roque Navarro, Lourdes Tatiana; Mateo De Acosta Del Rio, Cristina Maria
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the obtention of genetically-engineered antibodies from the P3 (AcM P3) murine monoclonal antibody which is produced by the , hybridoma deposited under number ECACC 94113026 in accordance with the Budapest treaty, and from the 1E10 (AcMai 1E10) anti-idiotype thereof which , is produced by hybridoma ECACC 97112901 with the purpose of obtaining , antibodies which have the same recognition properties as the originals but which are less immunogenic. The chimaeric antibodies contain the variable domains of murine immunoglobulin and the constant regions of human immunoglobulin. The humanised antibodies in addition to containing the , constant regions of human …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 8, 2002 and granted June 7, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 8, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 8, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.